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Abstract
The cytidine deaminases APOBEC3G and APOBEC3F exert anti–HIV-1 activity that is countered by the HIV-1 vif protein.
Based on potential transcription factor binding sites in their putative promoters, we hypothesized that expression of
APOBEC3G and APOBEC3F would vary with T helper lymphocyte differentiation. Naive CD4+ T lymphocytes were
differentiated to T helper type 1 (Th1) and 2 (Th2) effector cells by expression of transcription factors Tbet and GATA3,
respectively, as well as by cytokine polarization. APOBEC3G and APOBEC3F RNA levels, and APOBEC3G protein levels, were
higher in Th1 than in Th2 cells. T cell receptor stimulation further increased APOBEC3G and APOBEC3F expression in Tbet-
and control-transduced, but not in GATA3-transduced, cells. Neutralizing anti–interferon-c antibodies reduced both basal
and T cell receptor-stimulated APOBEC3G and APOBEC3F expression in Tbet- and control-transduced cells. HIV-1 produced
from Th1 cells had more virion APOBEC3G, and decreased infectivity, compared to virions produced from Th2 cells. These
differences between Th1- and Th2-produced virions were greater for viruses lacking functional vif, but also seen with vif-
positive viruses. Over-expression of APOBEC3G in Th2 cells decreased the infectivity of virions produced from Th2 cells, and
reduction of APOBEC3G in Th1 cells increased infectivity of virions produced from Th1 cells, consistent with a causal role for
APOBEC3G in the infectivity difference. These results indicate that APOBEC3G and APOBEC3F levels vary physiologically
during CD4+ T lymphocyte differentiation, that interferon-c contributes to this modulation, and that this physiological
regulation can cause changes in infectivity of progeny virions, even in the presence of HIV-1 vif.
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Introduction
APOBEC3G (hA3G) and APOBEC3F (hA3F), two of several
related cytidine deaminases, evolved to limit retrotransposition [1–
3]. Although the HIV-1 accessory protein vif depletes hA3G and
hA3F from the producer cell, hA3G and hA3F are packaged into
vif-deleted HIV-1 and significantly impair virion infectivity [4–6].
IFN-a, and certain cytokines and mitogens, have been implicated
in increasing hA3G and hA3F expression in certain cell types [7–
12]. However, little more is known regarding the transcriptional
regulation of APOBEC3s in CD4+ T lymphocytes [13]. We noted
several potential binding sites for GATA family transcription
factors [14], in addition to previously observed interferon-
responsive elements [7,12,15], in the putative promoter regions
of hA3G and hA3F. Since GATA3 is integral to the differentiation
of naı ¨ve CD4+ T helper cells into Type 2 (Th2) effectors, we
hypothesized that Type 1 (Th1) and Th2 effector lymphocytes
differed in their expression of hA3G and hA3F.
After naive CD4+ T lymphocytes interact with their cognate
antigen, IL-12 and interferon-c (IFN-c) signaling drive their
differentiation to a Th1 effector phenotype. In contrast, IL-4
signaling after antigen recognition drives differentiation of naı ¨ve
cells to a Th2 phenotype [16–18]. These subtypes of T helper cells
produce distinct cytokine profiles after subsequent activation. Th1
cells, when activated, produce IFN-c to activate cell-mediated
immunity. Th2 cells, however, secrete IL-4 and other cytokines
which augment humoral immune responses. The differentiation to
a Th1 or Th2 phenotype is dependent on the regulated expression
of two master transcriptional regulators, respectively: T Box
expressed in T cells (Tbet) and GATA3 [19–21]. Relative
differences in the ability of Th1 versus Th2 subtypes to produce
infectious wild-type HIV-1 progeny have been reported previously
in several studies and were not explained by differences in
expression of chemokine co-receptors for HIV entry [22–25].
Although high level over-expression of hA3G has been reported
to decrease infectivity of vif-positive virions produced from cell
lines in vitro [4,26–28], it is not known whether physiological
increases in hA3G or hA3F can overcome the effect of vif in
primary T cells. Reports conflict about whether differences in
levels of hA3G and hA3F in lymphocytes in vivo are inversely
associated with the level of wild-type HIV-1 RNA in plasma of
untreated patients [29–31]. One of two reports has correlated
provirus hypermutation attributable to hA3G and hA3F with
plasma viral load, consistent with effects in vivo against at least
some vif-positive viruses [32,33]. Since an effect of variation of
levels of hA3G and hA3F in a physiologically relevant range on
wild-type, vif-positive HIV-1 replication has not yet been directly
demonstrated, the present study aimed to define if such cellular
differences occur during Th1 versus Th2 differentiation and may
cause changes in HIV-1 infectivity that affect pathogenesis.
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Master Transcriptional Regulators Modulate APOBEC3G
and APOBEC3F Expression
Naı ¨ve CD4+ T cells from five individual HIV-1 negative donors
were transduced with HIV-derived lentiviral vectors that
expressed either GFP alone (control), or together with Tbet or
GATA3. Expression of GATA3 and Tbet were found to have
opposing effects on the expression of hA3G and hA3F mRNA by
qRT-PCR (Figure 1A and 1B). Whereas expression of GATA3
reduced the level of hA3G and hA3F, Tbet significantly increased
the levels of both enzymes. Based on these results, confirmation
that this was a statistically and biologically significant effect was
sought by studying Th1 versus Th2 differentiation using more
physiological cytokine polarization.
CD4+ T Helper Type 2 Lymphocytes Express Lower Levels
of APOBEC3G and APOBEC3F than T Helper Type 1
Lymphocytes
Th1 and Th2 cells were differentiated in vitro by culturing naı ¨ve
cells from nine individual donors in polarizing cytokines. Staining
for Th1- and Th2-associated intracellular cytokines (IFN-c and IL-
4, respectively) and surface markers (CXCR3 and CRTh2,
respectively) (Figure 2A), verified the phenotypes of the cytokine-
differentiated cells. Cytoplasmic RNA was isolated and the levels
of hA3G and hA3F mRNA were determined relative to GAPDH
expression by qRT-PCR. Th2 cells expressed significantly less
hA3G and hA3F mRNA than Th1 cells (Figure 2B and 2C).
Western blot analysis of the two helper cell subtypes revealed that
Th2 cells also expressed lower levels of hA3G protein than Th1
cells (Figure 2D and 2E). The statistically significant difference in
median hA3G mRNA levels, and in protein levels, between Th1
and Th2 cells was approximately 3-fold.
Interferon-c Regulates Basal and TCR-Stimulated
Expression of APOBEC3s in Tbet-Transduced Cells
Since previous studies have observed that mitogen treatment
increases hA3G expression [7], we tested whether T Cell Receptor
(TCR) stimulation would increase hA3G and hA3F expression in
Tbet and GATA3 expressing T-cells. Levels of hA3G and hA3F
RNAs increased after TCR stimulation of control vector- and
Tbet-transduced cells, while this did not occur with TCR
activation of GATA3-transduced cells (Figure 3A). A defining
characteristic of Th1 cells is their ability to produce IFN-c upon
activation, which then exerts autocrine effects [34]. It is also
known that GATA3 diminishes IFN-c expression. Therefore, the
hypothesis that IFN-c contributes to the observed increase in
hA3G and hA3F expression after TCR stimulation was tested by
performing TCR stimulation of control- and Tbet-transduced cells
in the absence or presence of a neutralizing anti- IFN-c antibody.
The presence of neutralizing anti- IFN-c antibody blocked the
TCR-stimulated increased transcription of hA3G and hA3F, and
reduced basal levels, in both control- and Tbet-transduced cells
(Figure 3B and 3C). This suggests that IFN-c contributes to
maintaining the steady state level of hA3G and hA3F in Th1 cells,
as well as in increasing expression after TCR activation.
Increased Infectivity of HIV-1 Produced from CD4+ T
Helper Type 2 Compared to Type 1 Lymphocytes
We next tested whether the differential expression of APO-
BEC3s between Th1 and Th2 cells led to a difference in infectivity
of HIV-1 virions produced from these cells. We infected TCR-
activated, cytokine-derived T helper cells with vif-deleted or vif-
competent HIV-1(NL4-3) produced from 293T cells (which do not
express hA3G or hA3F). Infected cells were washed 12 hours after
infection and new media containing reverse transcriptase inhib-
itors (didanosine and zidovudine) was added to prevent spread past
the first-round infected cells. Twelve hours after the new media
was added, the culture supernatant fluids were collected,
normalized by Gag p24 capsid antigen concentrations, and used
to infect the TZM-bl indicator cell line. Infectivity was determined
by luciferase activity. Figure 4A quantitates infectivity of wild-type
and vif-deleted viruses produced from Th1 and Th2 cells from one
of nine donors studied. Vif-negative viruses produced from Th2
cells from this individual were five-fold more infectious than those
produced from Th1 cells, whereas vif-competent virions from Th2
cells were three-fold more infectious than those produced from
Th1 cells (Figure 4A). The median infectivity of virions produced
from Th1 cells of all nine donors studied was significantly less than
that of viruses produced from all the different Th2 cells, whether
vif was present or not (Figure 4B and 4C). The magnitude of this
difference varied across different individual donors’ paired Th1
and Th2 cells, whether vif was present or not (Figure 4B and 4C;
each donor’s Th1 and Th2 cells are linked by a line). A3G protein
levels also varied, with Th1 cells having higher levels and a
broader range of hA3G protein than Th2 cells (comparing X-axis
in Figure 4D and 4E). Despite the small number of subjects and
variability of the assays, there was a suggestion of an inverse
correlation between A3G protein expression and infectivity of
virions produced from Th1 (+vif r=2.16, 2vif r=2.18; all
p.0.05) or Th2 (+vif r=2.28, 2vif r=2.01; all p.0.05). We
amplified a pol gene fragment from the TZM-bl cells infected for
60 hours with Th1- or Th2-produced vif-negative virions to
quantify if effects of cytidine deamination differed by cell type.
Hypermutation was not seen in HIV pol DNA amplified from cells
infected with virus produced from either cell type (data not shown),
using either population sequencing subsequent to standard PCR
or 3D PCR [35]. Although these data are consistent with direct
effects of hA3G and hA3F on infectivity of vif-competent HIV as
well as vif-defective HIV-1, it is possible that other variables may
affect infectivity of virions produced from these cytokine-polarized
cells.
Author Summary
Some host cell proteins can hinder, or restrict, the life cycle
of HIV-1. APOBEC3G and APOBEC3F are cellular enzymes
that decrease HIV-1’s ability to replicate in a subsequent
target cell if they are present in the virus particle. As a
countermeasure, HIV-1 virion infectivity factor (vif) induces
degradation of APOBEC3G and APOBEC3F, thereby pre-
venting themfromgetting into thebuddingvirus.Although
vif-defective viruses cannot evade the antiviral effect of
APOBEC3G, such viruses are very rarely present in HIV-1-
infected humans. It is not yet known whether physiological
variation in APOBEC3G and APOBEC3F expression in CD4+ T
lymphocytes is substantial enough to reduce vif-positive
HIV-1 infectivity. In this study, we found that T helper type 1
(Th1) cells, a subtype of CD4+ lymphocytes, expressed
greater amounts of APOBEC3G and APOBEC3F than T
helpertype2(Th2)cells.Thisdifferenceledtoadifferencein
infectivity of HIV-1 produced from the two cell types,
whether vif was expressed or not. These results demon-
strate that physiological regulation of APOBEC3G does
restrict vif-positive HIV-1, as well as vif-negative HIV-1. In
addition, this study reveals biological factors regulating
expression of these proteins that may be exploitable for
new therapeutic or preventive strategies against HIV-1.
T Cell APOBEC3G and HIV-1 Infectivity
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Th1- Versus Th2-produced HIV-1
To confirm a causal role for hA3G in the observed virion
infectivity differences we modulated expression of A3G in Th1 and
Th2 cells by increasing expression in Th2 cells and decreasing
expression in Th1 cells. We increased expression of hA3G in
cytokine-derived Th2 cells by transduction with a hA3G-
expressing lentiviral vector or an ‘‘empty’’ control vector for
comparison. Transduction of Th2 cells with the hA3G-expressing
vector increased hA3G levels 4 fold over Th1 cells and 7 fold over
Th2 cells (data not shown). After expansion, the unsorted
population of hA3G vector-transduced Th2 cells (Th2-A3G), as
well as Th1 and Th2 cells, were infected. The vif-deleted virions
produced from Th1, Th2 and Th2-A3G cells were concentrated
and the relative levels of virion packaged hA3G were determined
by Western blotting. Figure 5A demonstrates that vif-deleted
virions produced from Th1 cells contain more hA3G than virions
produced from Th2 cells. Th2-A3G cells produced virions with
more packaged hA3G than Th2 cells (Figure 5A). Transduction
with the empty vector (Th2-Empty) caused no increase in cellular
or virion hA3G levels, relative to untransduced Th2 cells (data not
shown). Virions produced from the Th2-A3G cells were
significantly less infectious than those produced from the Th2
cells transduced with the ‘‘empty’’ control vector (‘‘Th2-Empty’’)
(Figure 5B). There was an inverse correlation between virion (and
cellular) hA3G levels by western blot and virion infectivity.
Neutralizing anti-IFN-c antibody was used to decrease
expression of A3G in Th1 cells (as seen in Figure 3). Incubation
with neutralizing anti-IFN-c antibody, concurrent with activation,
reduced the expression of A3G in Th1 cells nearly 2 fold (relative
Figure 1. Tbet and GATA3 regulate hA3G and hA3F expression. Naı ¨ve CD4+ T cells were transduced with a Tbet or GATA3 expressing
lentiviral vector. After sorting based on GFP marker gene expression, cytoplasmic RNA was isolated and used to determine mRNA levels of hA3G (A)
and hA3F (B) by qRT-PCR. Data are expressed as copy number of hA3G or hA3F per 10
6 copies of GAPDH. Error bars represent median and
interquartile range.
doi:10.1371/journal.ppat.1000292.g001
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(Figure 5C, open bars). Virions produced from Th1 cells with
reduced hA3G had increased infectivity (Figure 5C, closed bars).
Taken together, these data indicate that variation in infectivity of
virions produced from cells is related to differences in hA3G
expression.
Discussion
In this study, we have shown that the expression and anti-HIV
function of hA3G and hA3F vary with naı ¨ve CD4+ T helper cell
differentiation to Th1 and Th2 effector cells. Cytokine polariza-
tion of naı ¨ve cells into Th1 and Th2 effectors had similar effects to
transduction of naı ¨ve cells with Tbet or GATA3. In both cases,
decreased expression of hA3G and hA3F was seen in Th2 cells
relative to Th1 cells. These complementary methods demonstrate
that the differences observed in the Tbet and GATA3 transduced
cells were due to transcription regulated by those factors and not
an artifact of over-expression. Such an opposing effect of
differentiation on expression of hA3G and hA3F is consistent
with earlier findings of opposing effects on the expression of several
other genes in these two T helper subtypes [21,36]. This hA3G
and hA3F expression difference between Th1 and Th2 cells
affected wild type, as well as vif-deleted, HIV-1 infectivity.
Expression of Tbet in naı ¨ve helper cells has been shown to lead
to production of IFN-c[Sfabo, 2000 #35]. In turn, that IFN-c
can act in an autocrine manner on Th1 cells [34]. Extracellular
neutralization of IFN-c secreted by Tbet-transduced and control-
transduced cells blocked basal and TCR-stimulated hA3G and
hA3F expression. This is consistent with an autocrine effect of
IFN-c regulating hA3G and hA3F expression. GATA3 is known
to inhibit the production of IFN-c [37] and no effect was observed
with neutralizing anti-IFN-c antibody or TCR stimulation of
GATA3-transduced cells. This may be due to a GATA3-mediated
block to production of IFN-c, or a direct effect of GATA3 binding
to the hA3G and hA3F promoters. These possibilities remain to be
directly tested.
We verified that the difference in expression in cytokine-derived
T helper cells led to a biological difference: infectivity of HIV-1
virions produced from Th1 and Th2 effectors varied inversely with
their relative levels of cellular and virion hA3G and hA3F.
Removal of vif resulted in reduced infectivity of virions produced
from both cell types. The greater reduction of infectivity of virions
produced from the Th1 cells is consistent with the relative greater
APOBEC3 levels in those cells. Over-expression of hA3G in Th2
cells reversed the relative decrease in virion hA3G and the
consequent relative increase in infectivity of virions produced from
Th2 cells. The magnitude of the effect of the ectopically-expressed
hA3G is likely underestimated here, as not every cell in this
population is expressing the transduced hA3G. In addition,
reduction of hA3G in Th1 cells also correlated with an increase
in infectivity. We used neutralizing anti-IFN-c antibody to
decrease hA3G expression in Th1 cells because shRNA against
hA3G or nucleofection (for introduction of siRNA against hA3G)
proved toxic to in vitro-derived Th1 cells, which are more prone to
cell death than other cultured T cells [38–40].These results are
consistent with the variation in virion infectivity being caused, at
least in part, by the differences in cellular and therefore virion
hA3G, rather than other effects of the cytokine derivation.
In this study, we observed reduction of infectivity associated
with increased amounts of readily detectable virion hA3G without
identification of any G-to-A hypermutation. Although hA3G and
hA3F are cytidine deaminases, there is extensive evidence that
hA3G also reduces HIV infectivity through other mechanisms that
may be the major contributor to A3G’s inhibition of reverse
transcription [26,33,41,42]. Previous studies that have observed
hA3G-related hypermutation in vitro differed from the short term
virus replication allowed here, and instead used prolonged serial
passage of HIV in transformed cell lines over-expressing hA3G
[43,44]. Therefore, it is likely that the difference in infectivity
based on cell source of virus observed here is due to the other
antiviral activities of hA3G that are not measured by hypermuta-
tion.
A major issue concerning the role of hA3G and hA3F in HIV-1
pathogenesis is the question of whether in vivo variation in these
cellular restriction factors affects replication of wild type (eg, vif-
competent) HIV-1. Although high level over-expression of hA3G
does impair replication of wild type HIV-1 in cell lines [4], more
recent studies have not conclusively determined if there is a
correlation between the variation in cellular hA3G expression
observed across HIV-infected individuals’ peripheral blood
mononuclear cells and the plasma viral load in these subjects
[29,30,32]. The present results clearly indicate that physiological
variations in hA3G levels in primary cells are inversely correlated
with hA3G content and infectivity of wild type virions. This more
direct measure of biological relevance observed here supports the
conclusions of earlier reports showing that greater A3G activity
was associated with lower viral load set-point [32], and suggests
that continued investigation of the effect of APOBEC3 restriction
factors on vif-competent HIV-1 pathogenesis in vivo is warranted.
The present results are also consistent with earlier reports that
HIV-1 spreads better through cultures of Th2 cells than Th1 cells
[24]. This effect was most apparent in the prior studies using
CXCR4 (X4) tropic viruses [25], such as the viruses used here, and
not explained by differences in expression of that co-receptor
between Th1 and Th2 cells. The present results suggest, however,
that virions produced from Th2 cells may be relatively more
infectious than those produced from Th1 cells because of their
relatively lower hA3G content. In an earlier study [25], CCR5-
tropic HIV replicated equally well in Th1 and Th2 cells. Th1 cells
express higher levels of CCR5 coreceptor than Th2 cells [21,22].
Indeed, X4-tropic viruses were chosen for study here to minimize
possible difficulty in interpretation of opposing effects of both
increased CCR5 co-receptor expression and increased A3G
expression in Th1 cell cultures, though further investigation into
how co-receptor tropism affects infectivity is certainly warranted.
Moreover, the wide inter-individual variation in hA3G and hA3F
expression in our results (a 14 fold range in hA3G protein
expression in Th1 cells and a four fold range in Th2 cells) suggests
that there may be polymorphisms in the regulatory regions of the
APOBEC3 promoters [45], or in factors that can modulate hA3G
and hA3F expression or function. We hypothesize that this
Figure 2. Th2 cells express lower levels of hA3G and hA3F than Th1. Naı ¨ve CD4+ T cells were derived to either a Th1 or Th2 phenotype using
cytokines as described in Materials and Methods. The cells were then stained for intracellular cytokine production or surface markers (A) to confirm
differentiation. Cytoplasmic RNA was isolated from the cells and used for qRT-PCR to determine the level of hA3G (B) or hA3F (C) mRNA. Error bars
represent media and interquartile range (*p=0.0039). In vitro cytokine-derived Th1 or Th2 cells were also lysed and subjected to Western Blotting
with a hA3G specific antibody and levels of expression were quantified using a LICOR Odyssey system. A representative blot is shown (D) as well as
the compilation of 8 individual donors (E) with quantities expressed as quantified intensity of hA3G bands per quantified intensity of Beta-Actin
bands of the same lane. Error bars represent median and interquartile range (*p=0.0078).
doi:10.1371/journal.ppat.1000292.g002
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PLoS Pathogens | www.plospathogens.org 5 February 2009 | Volume 5 | Issue 2 | e1000292Figure 3. Interferon gamma regulates expression of hA3G and hA3F in Tbet but not GATA3 transduced cells. Control, Tbet, and GATA3
transduced cells were TCR stimulated with CD3/CD28 beads. Cytoplasmic RNA was then isolated to determine the fold change in mRNA expression
by qRT-PCR (A). Control (B) and Tbet (C) transduced cells were TCR stimulated or left unstimulated in the presence of a neutralizing anti-interferon
gamma antibody. The fold change in mRNA expression was again determined by qRT-PCR. Incubation of TCR stimulated cells with isotype control
does not differ significantly from stimulation alone (data not shown). Error bars represent standard deviation from the mean.
doi:10.1371/journal.ppat.1000292.g003
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PLoS Pathogens | www.plospathogens.org 6 February 2009 | Volume 5 | Issue 2 | e1000292Figure 4. Increased Infectivity of HIV-1 produced from Th2 cells compared to Th1 cells. vif-competent (+)o rvif-deleted (2) HIV-1(NL4-3)
was used to infect cultures of Th1 and Th2 cells as described in Materials and Methods. Infectivity of the virions produced was determined by
infection of the TZM-bl indicator cell line and determination of luciferase activity. An example from an individual donor is shown (A). The experiment
was repeated on a total of seven donors with both the vif-competent (B) and vif-deleted virus(C). Error bars represent median and interquartile range
T Cell APOBEC3G and HIV-1 Infectivity
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of progression time to AIDS among different patients. The Th1/
Th2 cell balance may also vary across individuals based on several
factors. Autoimmunity may lead to a Th1 cell skewing and
parasitic infections may cause aTh2 cell predominance. Our
findings suggest that a shift in this balance prior to, or during,
of difference in infectivity of virions produced from Th1 cells versus Th2 cells for vif-positive virus (B; *p=.031) and vif-negative virus (C; **p=.016). To
test for correlation, individual donor cells’ levels of hA3G protein expression were plotted against infectivity of the vif-competent and vif-deleted
virions produced from that individual’s Th1 cells (D) and Th2 cells (E).
doi:10.1371/journal.ppat.1000292.g004
Figure 5. Evidence supporting a direct effect of hA3G on relative infectivity of HIV-1 virions produced from Th1 and Th2 cells. In
vitro cytokine-derived Th2 cells were transduced with a control lentiviral vector (Th2-Empty) or a vector expressing hA3G (Th2-A3G). Protein levelso f
hA3G packaged into virions produced from Th1, Th2, and hA3G-transduced Th2 cells were determined by Western Blotting on the LICOR Odyssey
system (Relative Light Units (RLU) of hA3G as normalized by HIV-1 p24 antigen) Shown is a representative blot of three experiments with similar
trends. (A). The infectivity of vif-deleted HIV-1(NL4-3) virions produced from those cells from 6 donors was determined using the TZM-bl indicator cell
line. Error bars represent median and interquartile range (*p=.03). (B) In vitro cytokine-derived Th1 cells were activated and incubated with eithera n
isotype control or neutralizing IFN-c antibodies for 48 hours. Protein concentrations were determined by Western blot (C,open bars). The infectivity
of vif-deleted HIV-1(NL4-3) virions produced from those cells was determined using the TZM-bl indicator cell line (C, closed bars).
doi:10.1371/journal.ppat.1000292.g005
T Cell APOBEC3G and HIV-1 Infectivity
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Decreased relative expression of hA3G and hA3F in Th2 cells may
lead to a greater rate of decrease in that cellular pool, decreasing
CD4+ help to B cells for antibody production. Also, an individual’s
variation in Th1/Th2 balance may lead to differences in HIV-1
genetic variation due to hA3G- and hA3F-mediated sub-lethal
cytidine deamination of viral genomes over repeated cycles of
infection [46].
The present study indicates that the regulation of expression of
hA3G and hA3F, and their functional effect on HIV-1 infectivity,
depends on the cytokine-regulated differentiation state of CD4+ T
helper cells. Further molecular characterization of signals that
modulate hA3G and hA3F expression will be needed. The current
results provide compelling evidence that increasing hA3G in
primary T cells impairs HIV-1 replication despite the presence of
Vif. This validates inducing higher hA3G expression as a novel
strategy for prevention of infection and/or treatment of the vif-
positive viruses present in infected humans.
Materials and Methods
Cells
Blood was obtained from healthy volunteers under a protocol
approved by the Vanderbilt Institutional Review Board. PBMCs
were isolated using Ficoll Hypaque (Amersham Biosciences).
CD4+ cells were isolated by negative selection through magnetic
separation using autoMacs (Miltenyi Biotec, Auburn, CA) or
Robosep (StemCell Technologies, Vancouver, BC. Canada).
Naı ¨ve cells were subsequently purified by staining with
CD45RO-FITC and CD25-PE (BD Pharmingen, San Jose, CA)
followed by sorting on a FACSAria (Becton Dickinson, San Jose,
CA). For activation and expansion, naı ¨ve cells were plated in wells
coated with an anti-CD3 antibody (OKT3; American Type
Culture Collection, Manassas, Virginia, United States) in RPMI
with 10% FBS supplemented with 1 mg/ml soluble anti-CD28
antibodies (BD Biosciences Pharmingen) and 50 U/mL human
rIL-2 (obtained from Dr. Maurice Gately, Hoffmann - La Roche
Inc. through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) [47]. DMEM with
10% FBS was used to culture TZM-bl cells (obtained from Dr.
John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. through the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH) [48].
Transduction and T Helper Cell Differentiation
Naı ¨ve CD4+ T cells were differentiated by transduction with
HIV derived lentiviral vectors expressing Tbet, GATA3, or a
control vector at the time of activation [49,50]. The vectors
express GFP alone (control), or the transcription factor and GFP,
from an IRES. After infection and activation, cells were expanded
for 10 days. Following expansion, cells were sorted on a FACSAria
for GFP expression.
To achieve Th1 cell differentiation using cytokine polarization,
naı ¨ve CD4+ T cells were plated on anti-CD3 (OKT3) coated
plates in RPMI supplemented with anti-CD28 antibodies, 0.5 mg/
mL neutralizing anti-IL-4 antibody and 30 ng/mL recombinant
IL-12. For Th2 cell differentiation by cytokines, naı ¨ve cells were
cultured in media supplemented with 2.5 mg/mL neutralizing
anti-IFN-c antibody and 50 ng/mL recombinant IL-4. Cytokines
and neutralizing antibodies were obtained from R&D Systems,
Minneapolis, MN. The cells were expanded for 10 days and
differentiation was confirmed by intracellular cytokine staining for
IL-4-PE and IFN-c-APC (BD Pharmingen, San Jose CA.) as
previously described [49], as well as surface staining for CXCR3-
PE and CRTh2-APC (BD Pharmingen, San Jose CA) [51–53]. To
increase APOBEC3G expression in cytokine polarized Th2 cells,
differentiating cultures were transduced with an APOBEC3G-
expressing HIV derived lentiviral vector at the time of activation.
The vector was constructed as other HIV derived lentiviral
expression vectors previously described to express hA3G and HSA
as a marker of transduction [50]. To reduce APOBEC3G
expression in cytokine polarized Th1 cells, fully differentiated
Th1 cells were activated for 48 hrs with CD3/CD28 coated beads
(Invitrogen) in the presence of 5 mg and 10 mg anti-IFN-c
antibody (R&D Systems).
Real Time PCR
Cytoplasmic RNA was isolated from cell pellets (Qiagen RNeasy,
Valencia, CA). RNA was quantified by spectrophotometry on a
GeneQuant Pro (Amersham Biosciences, Piscataway, NJ). RNA
concentrations were normalized and TaqMan quantitative real-time
RT-PCR was performed (Applied Biosystems Prism 7000 Sequence
Detection System, Foster City, CA). Reverse transcription used
hA3G and hA3F specific primers with the sequences 59-
GCGGCCTTCAAGGAAACC-39 and 59-TTTTAAAGTG-
GAAGTAGAATATGTGTGGAT-39, respectively. The primer-
probe set used for APOBEC3G real-time PCR was: forward: 59-
CTGCTGAACCAGCGCAGG-39 reverse: 59-GCGGCCTTCAA-
GGAAACC-39 and probe: 59-CTTTCTATGCAACCAGGCTC-
CACATAAAC-39. The set for APOBEC3F was: forward: 59-
GCACCGCACGCTAAAGGA-39,r e v e r s e5 9- TTTTAAAGTG-
GAAGTAGAATATGTGTGGAT -39 and probe: 59TTCTCA-
GAAACCCGATGGAGGCAATG-39. Values are expressed as
copies of target per million copies of GAPDH or calculated as fold
change using the delta-Ct method [54].
Western Blotting
Transduced or cytokine-derived T helper subtype cells were
lysed in 50 mM HEPES, pH 7.4, 125 mM NaCl, 0.2% NP-40,
0.1 mM PMSF and EDTA-free protease inhibitor cocktail
(CalBiochem, San Diego, CA). Protein concentrations were
normalized based on results of a Bradford Assay (Bradford Assay
reagent, Bio-Rad, Hercules, CA). Lysates were separated on a
SDS-PAGE gel and proteins were subsequently transferred to a
Trans-Blot nitrocellulose membrane (Bio-Rad, Hercules, CA).
The membrane was then incubated with a polyclonal anti-
APOBEC3G antibody [55], washed and probed with a goat anti-
rabbit secondary antibody conjugated with Alexa Fluor 680
(Invitrogen Molecular Probes, Carlsbad, CA). Fluorescent signal
was then measured using the Licor Odyssey system (LI-COR
Biosciences, Lincoln, Nebraska). Membranes were subsequently
probed with a monoclonal b-actin antibody (Sigma, St. Louis,
MO) followed by a sheep anti-mouse secondary antibody
conjugated with IR-Dye800 (Rockland Immunochemicals, Phila-
delphia, PA). APOBEC3G expression is expressed as fluorescent
intensity (Relative Light Units, RLU) of APOBEC3G bands
divided by the fluorescent intensity (RLU) of the b-actin band
[56]. For quantification of virion packaged APOBEC3G, virions
were concentrated by centrifugation of culture supernatants
through a 20% sucrose cushion at 125,0006g for 45 minutes
and normalized for their p24 content with viral lysis buffer
[50 mM Tris (pH 8.0), 40 mM KCl, 50 mM NaCl, 5 mM
Na2EDTA, 10 mM DTT and 0.1% (v/v) Triton X-100]. Lysates
were blotted as described above with anit-APOBEC3G and an
anti-HIV-1 capsid p24 antibody derived from the 183-H12-5C
hybridomas (obtained from Dr. Bruce Chesebro and Dr. Hardy
Chen through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH [57]). Data are
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divided by the fluorescent intensity (RLU) of the HIV-1 CA p24.
Viruses and Infectivity
HIV-1 was produced by calcium phosphate transfection of
293T cells using NL4-3 (obtained from Dr. Malcom Martin
through the NIH AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) [58] and vif-deleted
NL4-3 (a gift from the Chris Aiken Laboratory, constructed by
Hevey and Donehower) [59]. After determination of the
concentration of viral particles by HIV-1 CA p24 ELISA,
300 ng of p24-equivalents of HIV-1 were spinoculated (3006g,
30 min) on 1610
6 Th1, Th2, or TH2-A3G cells that had been
activated by anti-CD3/CD28 coated beads (Invitrogen Dynal,
Carlsbad, CA) for 60 hours [60]. Twelve hours after infection,
cultures were washed twice with PBS. The cells were then
resuspended in RPMI media containing 10 uM didanosine
(Sigma, St. Louis, MO) and 25 uM zidovudine (Sigma, St. Louis,
MO) to limit virus spread. After another 12 hrs in culture,
supernatant fluids were collected for p24 antigen ELISA. Equal
p24 concentrations of viral supernatant were then used to infect
the TZM-bl indicator cells [48] and luciferase activity was
determined in cell lysates 60 hours after infection (Bright-Glo
Luciferase assay substrate, Promega, Madison, WI; TopCount
scintillation counter, Packard/Perkin Elmer, Waltham, MA). Data
are shown as RLU per nanogram p24 CA added.
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